Meeting
2022 ASCO Annual Meeting
Early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer.
Authors
Xichun Hu
Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai, China
Xichun Hu , Jian Zhang , Nicholas Patrick McAndrew
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT04509596
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1038)
DOI
10.1200/JCO.2022.40.16_suppl.1038
Abstract #
1038
Poster Bd #
416
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.
First Author: Carey K. Anders
Poster
2021 ASCO Annual Meeting
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
First Author: Erica Michelle Stringer-Reasor
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
First Author: Fei Ma